Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 15,424 as of Tuesday, Sept. 24, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,875 issues advancing vs. 1,030 declining with 132 unchanged. The Health Care sector currently sits up 0.7% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the sector include Intuitive Surgical ( ISRG), down 1.0%, Celgene Corporation ( CELG), down 0.8%, Covidien ( COV), down 0.6% and Baxter International ( BAX), down 0.6%. Top gainers within the sector include Hologic ( HOLX), up 2.6%, Teva Pharmaceutical Industries ( TEVA), up 2.2%, WellPoint ( WLP), up 1.5%, Aetna ( AET), up 1.4% and UnitedHealth Group ( UNH), up 1.3%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Illumina ( ILMN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Illumina is down $0.95 (-1.2%) to $80.67 on average volume. Thus far, 391,001 shares of Illumina exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $79.49-$82.21 after having opened the day at $82.17 as compared to the previous trading day's close of $81.62. Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $10.1 billion and is part of the drugs industry. Shares are up 45.6% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold. TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.